Mode
Text Size
Log in / Sign up

Ibuprofen and acetaminophen show no statistically significant difference in total adverse events for pediatric painIbuprofen and acetaminophen show similar safety for children's pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that no statistically significant difference in adverse event risk exists between ibuprofen and acetaminophen in children.

This meta-analysis evaluates the safety profiles of ibuprofen and acetaminophen in children and adolescents aged 0 to 18 years. The analysis included data from various settings, including postoperative care, musculoskeletal trauma, orthodontic pain, and emergency department visits. The study analyzed total adverse events as the primary outcome, with secondary outcomes including gastrointestinal, renal, hepatic, and bleeding events.

The meta-analysis found no statistically significant difference in the risk of any adverse event between ibuprofen and acetaminophen (RR 0.80; 95% CI 0.36-1.79). Furthermore, no serious renal or hepatic adverse events were reported in the included data. The study notes that the certainty of the evidence is limited by the lack of large randomized controlled trials with standardized safety reporting.

Due to the limited certainty of the evidence, no clear difference in short-term safety was established. Clinicians should consider individual patient factors and specific clinical contexts when selecting between these two analgesics for pediatric patients.

How this fits prior evidence

This meta-analysis addresses a gap in comparing the safety of ibuprofen and acetaminophen in pediatric populations. While previous evidence noted that ibuprofen shows significant pain freedom for pediatric migraine treatment, this meta-analysis confirms that there is no statistically significant difference in total adverse events between ibuprofen and acetaminophen. The findings do not impact the reported finding that ibuprofen overdose is linked to bronchial ulceration in a single pediatric case, which remains hypothesis-generating.

When a child is in pain after an injury or a dental procedure, parents often have to choose between common medications like ibuprofen and acetaminophen. It can be hard to know which one is safer or more effective for a young person. This analysis looked at data from nearly 3,000 children and adolescents to see if one drug caused more problems than the other.

The researchers looked at various situations, including kids with muscle injuries, those in the emergency room, and those dealing with orthodontic pain. They tracked different types of issues, such as stomach problems, kidney issues, and liver problems. The results showed no statistically significant difference in the risk of any adverse events between the two medications. No serious kidney or liver problems were reported in the study.

While the data suggests both drugs are comparable in safety, the evidence is not yet certain. The researchers noted that the study's findings are limited and more large, standardized trials are needed to be sure. Because of this, doctors suggest that a child's specific needs and the situation should help guide the choice of which medicine to use.

What this means for you:
No significant difference in safety was found between ibuprofen and acetaminophen for children's pain.

Common questions

Is it safe to give ibuprofen or acetaminophen to children?

The study of 2,847 children and adolescents found no statistically significant difference in the risk of any adverse events between ibuprofen and acetaminophen. No serious renal or hepatic adverse events were reported in the data, suggesting both are comparable in safety for the groups studied.

Are there different side effects for these two medicines?

Researchers looked for specific issues like gastrointestinal, renal, hepatic, and bleeding events. They found no statistically significant difference between ibuprofen and acetaminophen regarding these types of side effects in the children and adolescents involved in the study.

How certain is the safety data for these medications?

The certainty of the evidence is currently limited. The researchers noted that more large, randomized controlled trials with standardized reporting are needed to provide a clearer picture of long-term safety and differences.

Study Details

Study typeMeta analysis
Sample sizen = 2,847
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
AIMS: The purpose of this study is to compare the safety of ibuprofen and acetaminophen (paracetamol) for acute mild-to-moderate pain in children and adolescents through a systematic review and meta-analysis. METHODS: PubMed, Scopus and Web of Science were searched from inception to May 2026 for randomized controlled trials (RCTs) in patients aged 0-18 years that reported safety outcomes. RCTs enrolling adult or mixed-age populations in acute pain settings were also considered eligible when paediatric-relevant safety data could be extracted. The review was conducted and reported in accordance with the PRISMA 2020 statement. Primary outcomes were total adverse events (AEs), gastrointestinal, renal, hepatic and bleeding events. The risk of bias was assessed using RoB 2. Random-effects meta-analyses were expressed as risk ratios (RR) with 95% confidence intervals (CI). RESULTS: Fifteen studies (2847 patients) were included across postoperative pain, musculoskeletal trauma, orthodontic pain and emergency department settings, with follow-up ranging from single-dose assessments to 12 months. Three studies, including 937 participants, contributed to the primary meta-analysis of any adverse event. Ibuprofen was not associated with a statistically significant difference in the risk of any adverse event compared with acetaminophen (RR 0.80, 95% CI 0.36-1.79; I = 2.9%). No serious renal or hepatic adverse events were reported. CONCLUSIONS: Available RCT evidence did not show a clear difference in short-term safety between ibuprofen and acetaminophen in paediatric and acute pain populations; however, the certainty of the evidence is limited. Patient factors and clinical context should guide drug choice. Larger RCTs with standardized safety reporting are needed.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.